Neurogene (NASDAQ:NGNE) Stock Rating Upgraded by Wall Street Zen

Neurogene (NASDAQ:NGNE – Get Free Report) was upgraded by equities researchers at Wall Street Zen from a “strong sell” rating to a “sell” rating in a report issued on Saturday, Wall Street Zen reports.

Several other equities analysts have also recently weighed in on the company. Canaccord Genuity Group lowered their target price on Neurogene from $180.00 to $166.00 and set a “buy” rating on the stock in a research note on Wednesday, August 12th. HC Wainwright reduced their price target on shares of Neurogene from $65.00 to $60.00 and set a “buy” rating for the company in a research report on Tuesday, November 10th. William Blair raised shares of Neurogene to a “strong-buy” rating in a research report on Wednesday, September 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of Neurogene in a report on Thursday, October 15th. Finally, JPMorgan Chase & Co. assumed coverage on shares of Neurogene in a research report on Thursday, October 8th. They set an “overweight” rating and a $60.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $79.57.

Check Out Our Latest Stock Analysis on NGNE

Neurogene Stock Performance

Shares of NGNE stock opened at $23.93 on Friday. Neurogene has a 1-year low of $15.93 and a 1-year high of $43.66. The company has a market capitalization of $495.35 million, a price-to-earnings ratio of -4.70 and a beta of 1.75. The stock’s fifty day simple moving average is $28.21 and its 200-day simple moving average is $28.08.

Neurogene (NASDAQ:NGNE – Get Free Report) last posted its quarterly earnings results on Monday, November 9th. The company reported ($1.05) earnings per share for the quarter, beating the consensus estimate of ($1.36) by $0.31. On average, sell-side analysts predict that Neurogene will post -5.26 EPS for the current year.

Institutional Trading of Neurogene

Several hedge funds and other institutional investors have recently modified their holdings of the company. Marshall Wace LLP acquired a new stake in Neurogene during the third quarter valued at $4,688,000. Empowered Funds LLC purchased a new position in Neurogene in the third quarter valued at about $349,000. State Street Corp grew its stake in Neurogene by 22.4% in the third quarter. State Street Corp now owns 549,269 shares of the company’s stock valued at $15,281,000 after purchasing an additional 100,625 shares in the last quarter. Keybank National Association OH acquired a new position in Neurogene in the 3rd quarter worth about $221,000. Finally, Alps Advisors Inc. increased its position in Neurogene by 65.4% in the 3rd quarter. Alps Advisors Inc. now owns 26,528 shares of the company’s stock worth $738,000 after purchasing an additional 10,488 shares during the last quarter. 52.37% of the stock is currently owned by hedge funds and other institutional investors.

Neurogene News Summary

These are some of the NGNE news items that stood out recently:

  • Positive Sentiment: HC Wainwright raised its 2026 and 2027 earnings-per-share estimates, projecting narrower losses across the periods and lifting its FY2027 estimate to a loss of $4.80 per share from $4.99. The firm maintained its Buy rating and $60 price target. HC Wainwright forecast for Neurogene
  • Positive Sentiment: Canaccord Genuity also reaffirmed its Buy rating on Neurogene, signaling continued analyst confidence. Canaccord Genuity keeps Buy rating
  • Negative Sentiment: Despite the improved estimates, HC Wainwright still expects Neurogene to report losses in 2026 and 2027, underscoring its ongoing financial risk.

About Neurogene

(Get Free Report)

Neurogene Inc. is a clinical-stage biotechnology company developing genetic medicines for rare neurological diseases. Its work focuses on using gene therapy to address the underlying causes of disorders with limited treatment options. The company’s lead program, NGN-401, is an investigational gene therapy for Rett syndrome, a rare genetic disorder that primarily affects girls and can cause significant developmental and neurological challenges. Neurogene is also advancing a broader pipeline of potential genetic medicines for rare diseases.

Further Reading

Analyst Recommendations for Neurogene (NASDAQ:NGNE)

Receive News & Ratings for Neurogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurogene and related companies with MarketBeat.com's FREE daily email newsletter.